Aro Biotherapeutics Reports Preliminary Efficacy for ABX1100, a Muscle-targeted GYS1 siRNA, in Patients with Late-Onset Pompe ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results